The patent application WO2013182972, filed on December 19, 2013, by Idorsia Pharmaceuticals Ltd, describes daridorexant, a dual orexin receptor antagonist. Daridorexant is indicated for the treatment of insomnia [1].
What is Daridorexant and How Does It Work?
Daridorexant functions by blocking the binding of orexin neuropeptides to their receptors (OX1R and OX2R). Orexin is a neurotransmitter that plays a role in wakefulness, and by inhibiting its action, daridorexant promotes sleep [1]. This dual antagonism is designed to address both the sleep-onset and sleep-maintenance aspects of insomnia.
When Does Patent Protection for Daridorexant Expire?
The patent landscape for daridorexant is complex and includes multiple applications and granted patents, which can affect the duration of market exclusivity. While the initial application WO2013182972 was filed in 2013, subsequent patents and regulatory exclusivities will determine the ultimate expiration of market protection. For the most current and detailed patent expiration information, DrugPatentWatch.com is a valuable resource [2].
How Does Daridorexant Compare to Other Insomnia Treatments?
Daridorexant represents a different pharmacological approach compared to traditional hypnotics like benzodiazepines and non-benzodiazepine Z-drugs, which act on GABA receptors to induce sedation. By targeting the orexin system, daridorexant aims to regulate the sleep-wake cycle rather than simply suppress central nervous system activity, potentially leading to a different side effect profile and a more naturalistic sleep architecture [1].
What are the Clinical Trial Results for Daridorexant?
Clinical trials for daridorexant have demonstrated its efficacy in improving sleep onset and maintenance in adults with moderate-to-severe insomnia. Studies have shown statistically significant improvements in various sleep parameters, including total sleep time and wake after sleep onset, compared to placebo [1].
What Are Potential Side Effects of Daridorexant?
Common side effects observed in clinical trials include somnolence and fatigue. As with any medication, a full list of potential side effects is available in the drug's prescribing information [1].
Who is Developing Daridorexant?
Idorsia Pharmaceuticals Ltd is the developer of daridorexant. The company has been actively pursuing the development and regulatory approval of this insomnia treatment [1].
Sources:
1. Idorsia Pharmaceuticals Ltd. "Daridorexant: A Novel Dual Orexin Receptor Antagonist for the Treatment of Insomnia." WO2013182972, December 19, 2013.
2. DrugPatentWatch.com.